The Hidden Cost of Innovation: How Drug Pricing Fuels Healthcare Disparities
Written By Helen Zhang
We are fortunate to be living in an era of medical innovation, frequently celebrating breakthroughs that offer hope for treating once-incurable diseases. Yet a critical barrier is often overlooked: the exorbitant prices of these treatments. While the medical community and the public marvel at these advancements, what use are they if they are prohibitively expensive and inaccessible to those who need it most?
The Current Reality of Drug Pricing
Amid headlines hailing revolutionary new drugs, the staggering costs (often in the millions) are rarely scrutinised. Pharmaceutical companies claim that these high prices reflect the high risks and cost of research and development (R&D), as well as the value that these drugs bring. However, studies show no direct relationship between R&D costs and drug prices. Instead, monopolistic practices, opaque pricing models, and predatory pricing strategies are the primary drivers of the crisis.
Monopolies and Patent Abuse
Patents are a way to encourage and reward innovation by granting inventors temporary monopolies, giving the opportunity to recoup R&D investments. Once patents expire (usually after 20 years), emerging competition from generics or biosimilars drive prices down, ensuring equitable access. However, companies exploit loopholes, using tactics like ‘evergreening’ (patenting minor modifications like dosage reformulation or delivery mechanisms), creating ‘patent thickets’ (numerous, often-overlapping patents) and ‘pay-for-delay’ agreements (financially incentivising generic competitors to delay market entry) to artificially maintain monopolies and inflate prices indefinitely.
Inelastic Demand and Predatory Pricing
Life-saving treatments are necessities, not luxuries. This means they have inelastic demand, as patients have little choice but to pay regardless of cost. This allows for pharmaceutical companies to set exorbitant prices. For example, cancer drugs often must be used sequentially, meaning a question of ‘when’ not ‘if’ a patient needs a specific drug, ensuring consistent demand. Furthermore, by the time a patent expires, drugs in this field are often already replaced with ‘new and improved’ versions under fresh patents, restarting the monopoly timeline. Similarly, biologics like insulin (which lack affordable generic equivalents due to the compound’s complexity) were unaffordable despite having little patent protection of the compound itself, due to companies maintaining monopolies by having patents elsewhere like delivery products (insulin pens) and through anti-competition measures like pricing out newcomer competitors.
However, 2023 marked a turning point in the U.S. insulin market. The ‘Big Three’ insulin manufacturers (controlling over 90% of global insulin supply) announced list price reductions of 65% to 80%, effectively bursting the U.S. insulin pricing bubble. A significant factor behind this decision was impending Medicaid rebate reforms set to take effect in 2024. Analysts estimate pricing cuts could save manufacturers hundreds of millions of USD in rebates to the federal government while simultaneously boosting profits. This serves as an example of how policy and public pressure can force the pharmaceutical industry to adopt more reasonable pricing strategies, which is a crucial precedent for tackling broader health inequities.
Lack of Transparency in Negotiations
Widespread use of confidential discounts and opaque negotiations further exacerbate inequalities. Pharmaceutical companies charge countries different prices based on their perceived ability to pay. If final prices negotiated confidentially reflect each health system’s ability to pay, such a pricing scheme would allow manufacturers to serve more markets than might be possible with more transparent pricing. However, secretive negotiations are just as likely to result in lowest prices for countries with the greatest negotiating power. This will not necessarily mean lower prices for poorer countries, as secrecy makes it virtually impossible to guard against such inequity in final pricing.
Why Drug Pricing Must Change - The Effects on Public Health
Examples from history
For decades, unaffordable medicines and inequitable access were seen as issues affecting mainly developing countries. This disparity was highlighted in the late 1990s, when the high cost of HIV/AIDS antiretroviral treatment left poorer nations without access to life-saving drugs. Despite the low production cost (around a few hundred dollars), companies maintained high prices (around fifty times production costs) due to patent monopolies, despite often being supported by government research. Thus, life-saving medicines were controlled by for-profit companies that prioritised profit maximisation over people’s health. By selling primarily to wealthy countries able to pay higher prices, less economically developed countries were deprived of access to critical drugs. This was a contributing factor to consequences such as the explosion of the HIV/AIDS crisis in much of the developing world.
This was echoed in the recent COVID-19 pandemic, where breakthrough vaccines were under monopoly control under a handful of companies. This resulted in what was dubbed as ‘vaccine apartheid’, in which wealthy countries hoarded vaccines for their population first, creating major global health inequities and delays in access for people in developing countries. Despite the lessons from the AIDS epidemic, the mistakes and consequences of COVID-19 highlights the ongoing issues of patent-driven inequities.
How Drug Pricing Should Be Set
To ensure fair and equitable access to medicines, drug pricing should be grounded in value for public health while providing reasonable returns for innovation. Governments must adopt policies that prevent exploitative pricing practices and align pharmaceutical prices to reflect comparative value for money, while still rewarding companies for R&D initiatives and innovations. If such pricing would result in underinvestment in desirable sectors for pharmaceutical R&D, there must be mechanisms to separate R&D costs from final pricing. Early and sustained price competition is critical, but must be regulated to avoid it being blown out of proportion, and cartels - or oligopoly collusions - should be supervised.
Emphasise Equity and Transparency
A fair drug pricing model must prioritise transparency and equity. Greater regulations over the industry by boards would ensure more accountability to companies. One approach to European pricing transparency could be expanding the regulatory scope of the European Medicines Agency (EMA) to include assessing the therapeutic value of new drugs compared to existing treatments. This would ensure pricing aligns with genuine innovation and public benefit.
Adopt Tiered Pricing and Budgeting
Drugs should be grouped into therapeutic classes with standardised costs. Prices for patented drugs may remain higher but within reasonable limits, thereby allowing governments to transition from arbitrary price negotiations to fixed budgets, ensuring predictable and equitable spending across therapeutic categories.
The Path Forward
There must be a change in the current environment of the pharmaceutical industry from monopolistic practices to models that balance innovation with affordability. Medical innovation is celebrated and rightly so, but there is much to be done on all levels to translate these innovations into real-world benefits for people globally. Achieving this requires commitment from (and between) governments, regulatory bodies and the industry to adopt equitable policies, foster transparency, and prioritise global healthcare access and health. Only then can we ensure that these groundbreaking innovations are not just created, but reach those who need them most.
Read the rest of the edition here
